Bispecific antibodies for cancer therapy
“The present and future of bispecific antibodies for cancer therapy”
Authors: Christian Klein, Ulrich Brinkmann, Janice Reichert and Roland Kontermann
“Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer and 3 for non-oncology indications.
This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell and checkpoint inhibitors.”
Source: Jean-Charles Soria/LinkedIn
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023